Eli Lilly to start late-stage trials of solanezumab in Alzheimer's disease

Eli Lilly announced Thursday that two separate randomised Phase III studies of solanezumab will begin enrolling patients this month to investigate whether the compound will slow the cognitive and functional decline of patients with mild-to-moderate Alzheimer's disease, compared with placebo.

The EXPEDITION trials are expected to enrol a total of 2000 patients aged 55 years and over who will be administered either placebo or intravenous solanezumab once every four weeks for 18 months. The drugmaker released Phase II study results for the anti-amyloid beta monoclonal antibody last year.

To read more Top Story articles, click here.